Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immunic, Inc.
  6. Summary
    IMUX   US4525EP1011

IMMUNIC, INC.

(IMUX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
8.32(c) 8.53(c) 8.5(c) 8.52(c) 8.32(c) Last
197 035 118 233 120 263 172 630 156 873 Volume
-3.37% +2.52% -0.35% +0.24% -2.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -90,6 M - -
Net cash position 2021 83,7 M - -
P/E ratio 2021 -2,14x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -94,7 M - -
Net Debt 2022 11,0 M - -
P/E ratio 2022 -2,41x
Yield 2022 -
Capitalization 218 M 218 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 52
Free-Float 75,4%
More Financials
Company
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is... 
More about the company
Ratings of Immunic, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about IMMUNIC, INC.
11/23Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare ..
PR
11/18Immunic Enrolls First Patient in Late Stage Study to Treat Relapsing Multiple Sclerosis
MT
11/18Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vi..
PR
11/18Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vi..
CI
11/04Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activi..
PU
11/04IMMUNIC, INC. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
11/04IMMUNIC, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/04Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/04IMMUNIC : Q3 Earnings Snapshot
AQ
11/04Earnings Flash (IMUX) IMMUNIC Posts Q3 Loss $-0.76, vs. Street Est of $-0.75
MT
11/04Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activi..
PR
11/01Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2..
PR
10/28Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-..
PR
10/28Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-..
CI
10/27Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IM..
PR
More news
News in other languages on IMMUNIC, INC.
07/19Immunic conclut un placement d'actions ordinaires
07/15Immunic lance une offre d'actions ordinaires pour un montant de 45 millions $.
07/15MISE À JOUR : Immunic propose une offre d'actions, mais les conditions ne sont pas encore ..
07/14Immunic propose une offre d'actions, mais les conditions ne sont pas encore fixées.
07/01Immunic obtient l'autorisation de la FDA pour lancer des essais sur des traitements con..
More news
Analyst Recommendations on IMMUNIC, INC.
More recommendations
Chart IMMUNIC, INC.
Duration : Period :
Immunic, Inc. Technical Analysis Chart | IMUX | US4525EP1011 | MarketScreener
Technical analysis trends IMMUNIC, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 8,32 $
Average target price 54,50 $
Spread / Average Target 555%
EPS Revisions
Managers and Directors
Daniel Vitt President, Chief Executive Officer & Director
Glenn Whaley VP-Finance, Chief Financial & Accounting Officer
Duane D. Nash Executive Chairman
Hella Kohlhof Chief Scientific Officer
Andreas Muehler Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
IMMUNIC, INC.-44.28%218
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819